In "Return to the Black Death" by Susan Scott and Christopher Duncan, it is argued (and rather well!) that a virus like the ones from the filovirus family, was the causative agent of the Black Death. Ebola virus is a member of the filovirus family.
Well, today I stumbled upon an article which argues for the efficacy of a cancer drug in Ebola infection. It made me think of why on earth they would even make such a study on the first place. Ebola is extremely rare compared to other infections, and there are enough infectious diseases to tackle already. It seems to me that there really isn't a very good reason to see what might or might not work on a rare infectious disease like Ebola. But then, maybe they have a very good reason...
The other interesting thing about the article is that they used imatinib for the study which has also been speculated to work against smallpox and which we already thought as having a relation to the Black Death:
What we do know is that a more virulent form of smallpox came to the fore in the 1630s and, just as the Black Death disappeared from the stage of history, smallpox took its place as the most feared of human diseases. We can only speculate. Smallpox virus, as opposed to the causative agent of the Black death, is very resistant to cold temperatures, making it a more viable virus. According to the data collected by Scott and Duncan which describe the disease process of the Black Death, hemorrhagic smallpox is almost virtually identical to the Black Death.
The cancer drug and Ebola article:
Cancer drugs could halt Ebola virus
Some cancer drugs used to treat patients with leukemia may also help stop the Ebola virus and give the body time to control the infection before it turns deadly, US researchers said on Wednesday.
The much-feared Ebola virus emerged in Africa in the 1970s and can incite a hemorrhagic fever which causes a person to bleed to death in up to 90 percent of cases.
While rare, the Ebola virus is considered a potential weapon for bioterrorists because it is so highly contagious, so lethal and has no standard treatment.
But a pair of well-known drugs that have been used to treat leukemia -- known as nolitinib and imatinib -- appear to have some success in stopping the virus from replicating in human cells.
Lead researcher Mayra Garcia of the US National Institute of Allergy and Infectious Diseases and colleagues reported their finding in Wednesday's edition of the journal Science Translational Medicine.
By experimenting with human embryonic kidney cells in a lab, they found that a protein called c-Abl1 tyrosine kinase was a key regulator in whether the Ebola virus could replicate or not.
The leukemia drugs work by stopping that protein's activity. In turn, a viral protein called VP40 stopped the release of viral particles from the infected cells, a process known as filovirus budding.
"Drugs that target filovirus budding would be expected to reduce the spread of infection, giving the immune system time to control the infection," the study authors wrote.
"Our results suggest that short-term administration of nilotinib or imatinib may be useful in treating Ebola virus infections."
Imatinib, which is marketed as Gleevec and Glivec, is used to treat chronic myelogenous leukemia in humans, a disease which is caused by dysregulation of c-Abl enzyme.
Nilotinib, also known as Tasigna, has been used in chronic myelogenous leukemia patients who are resistant to imatinib.
Both "have reasonable safety profiles, although some cardiac toxicity has been reported with long-term administration in a small number of patients," the study added.
According to the UN's World Health Organization (WHO), about 1,850 cases of Ebola, with some 1,200 deaths, have occurred since 1976.
The virus has a natural reservoir in several species of African fruit bat. Gorillas and other non-human primates are also susceptible to the disease.
Well, it does suggest that their treatment might counteract a terrorist attack with Ebola